Director, External Corporate Communications
Listed on 2026-10-01
-
Marketing / Advertising / PR
Marketing Communications
About Us:
Eupraxia is a clinical-stage biotechnology company focused on developing locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Diffu Sphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support an extended duration of effect and delivery of drugs in a hyper-localized fashion, targeting only the tissues that physicians want to treat.
We believe the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the Diffu Sphere™ technology, versus the peaks and troughs seen with more traditional drug delivery methods. The precision of Eupraxia's Diffu Sphere™ technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy and duration of effect.
The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, also to be applicable in oncology, infectious disease and other critical disease areas.
Eupraxia's EP-104GI is currently running both a Phase 1b/2a and Phase 2b trial, the RESOLVE trials, for the treatment of EoE. EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. This is a unique treatment approach for EoE. In addition, Eupraxia is developing a pipeline of later and earlier-stage long-acting formulations. Potential pipeline indications include candidates for GI diseases, inflammatory diseases and oncology, each designed to improve on the activity and tolerability of currently approved drugs.
For further details about Eupraxia, please visit the Company's website at:
Scope:
Eupraxia Pharmaceuticals is seeking a dynamic Director of External Communications with extensive experience within the biotech/pharma space, with specific experience working at a development stage company with a Phase 2/3 product. This position will play a key role generating the external corporate communications strategy to ensure the company's evolving story is communicated effectively. This position will work across functional areas including commercial, investor relations, clinical, medical affairs, research and HR.
They will be the point person for generating, reviewing and deploying external communication initiatives across various mediums (with subject matter expertise assistance) and responsible for corporate communications across multiple channels and platforms, including press releases, traditional and social media and for ensuring consistency of communications between corporate and communications and communications at scientific conferences.
Reports to:
Chief Corporate Development Officer
Location:
Seattle, WA or Vancouver, BC (hybrid work environment)
Key Responsibilities:
Corporate and Brand Messaging
- Develop communication strategies and plans that effectively communicate corporate and product stories to external audiences.
- Partner and coordinate with the executive team and other functional team members in the overall stewardship of the corporate brand, positioning and messaging.
- Own the process of creating and update company's overarching narrative and message architecture, ensuring consistency across the website, investor materials, social channels, commercial and medical communications.
- Navigate the process of obtaining approval for the Corporate Branding strategy and content by the Executive Team and other key stakeholder
Content Creation
- Develop and draft external communications materials,…
(If this job is in fact in your jurisdiction, then you may be using a Proxy or VPN to access this site, and to progress further, you should change your connectivity to another mobile device or PC).